A multi-modal deep learning solution for precise pneumonia diagnosis: the PneumoFusion-Net model DOI Creative Commons
Yujie Wang, Can Liu, Yu-Yan Fan

et al.

Frontiers in Physiology, Journal Year: 2025, Volume and Issue: 16

Published: March 12, 2025

Background Pneumonia is considered one of the most important causes morbidity and mortality in world. Bacterial viral pneumonia share many similar clinical features, thus making diagnosis a challenging task. Traditional diagnostic method developments mainly rely on radiological imaging require certain degree consulting experience, which can be inefficient inconsistent. Deep learning for classification multiple modalities, especially integrating data, has not been well explored. Methods The study introduce PneumoFusion-Net, deep learning-based multimodal framework that incorporates CT images, text, numerical lab test results, radiology reports improved diagnosis. In experiments, dataset 10,095 images was used-including associated data-most used training validation while keeping part it held-out set. Five-fold cross-validation order to evaluate this model, calculating different metrics including accuracy F1-Score. Results achieved 98.96% with 98% F1-score set, highly effective distinguishing bacterial from types pneumonia. This beneficial diagnosis, reducing misdiagnosis further improving homogeneity across various data sets patients. Conclusion PneumoFusion-Net offers an efficient approach by diverse sources, resulting high accuracy. Its potential integration could significantly reduce burden providing radiologists clinicians robust, automated tool.

Language: Английский

Biomarkers of aging DOI Open Access

Hainan Bao,

Jiani Cao, Mengting Chen

et al.

Science China Life Sciences, Journal Year: 2023, Volume and Issue: 66(5), P. 893 - 1066

Published: April 11, 2023

Language: Английский

Citations

197
Aggregation‐induced emission luminogens for in vivo molecular imaging and theranostics in cancer DOI Creative Commons
Peili Cen, Jiani Huang, Chentao Jin

et al.

Aggregate, Journal Year: 2023, Volume and Issue: 4(5)

Published: May 6, 2023

Abstract Cancer is one of the most fatal diseases for decades. Aggregation‐induced emission luminogens (AIEgens) have been recently used as molecular imaging or therapeutic agents in cancers, due to advantages large Stokes shift, high quantum yield, great biocompatibility, and strong photostability. AIEgens can specifically target different types cancer via diverse targeting strategies. AIEgen‐based fluorescence imaging, especially near‐infrared demonstrated deep penetration suitable signal‐to‐noise ratio, which allows reliable vivo imaging. Combined with other modalities, multimodal could provide multidimensional hallmarks from perspectives. In addition, phototherapy be photodynamic therapy photothermal therapy, facilitate ablation cells good biosafety effects vivo. nanoparticles fabricated some specific chemicals, drugs, siRNA, display synergistic cancers. This paper comprehensively describes current status future perspectives AIEgens, showed a potential preclinical clinical translation on theranostics cancer.

Language: Английский

Citations

92
Phenomic Studies on Diseases: Potential and Challenges DOI Creative Commons
Weihai Ying

Phenomics, Journal Year: 2023, Volume and Issue: 3(3), P. 285 - 299

Published: Jan. 5, 2023

Abstract The rapid development of such research field as multi-omics and artificial intelligence (AI) has made it possible to acquire analyze the multi-dimensional big data human phenomes. Increasing evidence indicated that phenomics can provide a revolutionary strategy approach for discovering new risk factors, diagnostic biomarkers precision therapies diseases, which holds profound advantages over conventional approaches realizing medicine: first, patients' phenomes remarkably richer information than genomes; second, phenomic studies on diseases may expose correlations among cross-scale parameters well mechanisms underlying correlations; third, phenomics-based are data-driven studies, significantly enhance possibility efficiency generating novel discoveries. However, still in early developmental stage, facing multiple major challenges tasks: there is significant deficiency analytical modeling analyzing phenomes; crucial establish universal standards acquirement management patients; methods devices patients under clinical settings should be developed; fourth, significance regulatory ethical guidelines diseases; fifth, important develop effective international cooperation. It expected would profoundly comprehensively our capacity prevention, diagnosis treatment diseases.

Language: Английский

Citations

49
Structural, Functional, and Molecular Imaging of Autism Spectrum Disorder DOI
Xiaoyi Li, Kai Zhang, Xiao He

et al.

Neuroscience Bulletin, Journal Year: 2021, Volume and Issue: 37(7), P. 1051 - 1071

Published: March 29, 2021

Language: Английский

Citations

61
International consensus on the use of tau PET imaging agent 18F-flortaucipir in Alzheimer’s disease DOI Creative Commons
Mei Tian, A. Cahid Civelek, Ignasi Carrió

et al.

European Journal of Nuclear Medicine and Molecular Imaging, Journal Year: 2022, Volume and Issue: 49(3), P. 895 - 904

Published: Jan. 3, 2022

Positron emission tomography (PET) with the first and only tau targeting radiotracer of 18F-flortaucipir approved by FDA has been increasingly used in depicting pathology deposition distribution patients cognitive impairment. The goal this international consensus is to help nuclear medicine practitioners procedurally perform PET imaging.A multidisciplinary task group formed experts from various countries discussed for imaging Alzheimer's disease (AD), focusing on clinical scenarios, patient preparation, administered activities, as well image acquisition, processing, interpretation, reporting.This practice guideline will promote standardized use AD. It become an standard purpose practice.

Language: Английский

Citations

43
PET molecular imaging for pathophysiological visualization in Alzheimer’s disease DOI Creative Commons
Jing Wang, Chentao Jin,

Jinyun Zhou

et al.

European Journal of Nuclear Medicine and Molecular Imaging, Journal Year: 2022, Volume and Issue: 50(3), P. 765 - 783

Published: Nov. 14, 2022

Alzheimer's disease (AD) is the most common dementia worldwide. The exact etiology of AD unclear as yet, and no effective treatments are currently available, making a tremendous burden posed on whole society. As multifaceted heterogeneous disease, biomarkers dynamic in course AD, range should be established to evaluate severity prognosis. Positron emission tomography (PET) offers great opportunity visualize from diverse perspectives by using radiolabeled agents involved various pathophysiological processes; PET imaging technique helps explore pathomechanisms comprehensively find out appropriate biomarker each phase, leading better evaluation disease. In this review, we discuss application summarized compounds with favorable characteristics.

Language: Английский

Citations

40
Microglial Activation Visualized by [18F]‐DPA714 PET Is a Potential Marker of Severity and Prognosis for Anti‐LGI1 Encephalitis DOI Creative Commons
Jingguo Wang, Jingjie Ge, Bo Deng

et al.

European Journal of Neurology, Journal Year: 2025, Volume and Issue: 32(3)

Published: March 1, 2025

Whether microglial activation plays an important role in the pathogenesis of autoimmune encephalitis (AE), such as anti-leucine-rich, glioma-inactivated-1 (LGI1) encephalitis, remains unknown. [18F]-DPA714 PET targeting translocator protein (TSPO) is a novel method to detect neuroinflammation via visualizing activated microglia. In this study, we aimed investigate application anti-LGI1 encephalitis. Patients with and non-inflammatory controls (NIC) underwent scans were enrolled. Standardized uptake value ratios normalized cerebellum (SUVRc) LGI1-AE patients calculated for semi-quantitative analysis. The marker, soluble triggering receptor expressed on myeloid cells 2 (sTREM2) was measured cerebrospinal fluid (CSF) demonstrate its correlation imaging. Logistic regression analysis used identify potential predictors prognosis. Forty-six included study. Increased TSPO identified hippocampus, frontal cortex, caudate nucleus. Montreal Cognitive Assessment (MoCA) score significantly correlated SUVRc hippocampus (R2 = 0.13, p 0.034) cortex 0.017). Overexpressed sTREM2 CSF 0.18, 0.04). decreased after immunotherapy associated improvement MoCA 0.54, 0.023). unfavorable disability recovery (odds ratio [OR] 7.1, 95% CI 1.67-29.9, 0.008) persistent amnesia (OR 5.4, 1.3-22.2, 0.021) respectively. Microglial visualized by clinical features may be biomarker therapeutic prognostic evaluation.

Language: Английский

Citations

1
International Nuclear Medicine Consensus on the Clinical Use of Amyloid Positron Emission Tomography in Alzheimer’s Disease DOI Creative Commons
Mei Tian, Chuantao Zuo, A. Cahid Civelek

et al.

Phenomics, Journal Year: 2022, Volume and Issue: 3(4), P. 375 - 389

Published: Aug. 26, 2022

Alzheimer's disease (AD) is the main cause of dementia, with its diagnosis and management remaining challenging. Amyloid positron emission tomography (PET) has become increasingly important in medical practice for patients AD. To integrate update previous guidelines field, a task group experts several disciplines from multiple countries was assembled, they revised approved content related to application amyloid PET settings cognitively impaired individuals, focusing on clinical scenarios, patient preparation, administered activities, as well image acquisition, processing, interpretation reporting. In addition, expert opinions, practices, protocols prominent research institutions performing dementia are integrated. With increasing availability imaging, complete standard pipeline entire examination process essential practice. This international consensus guideline will help promote proper use imaging

Language: Английский

Citations

36
Enhanced Therapeutic Efficacy of Combining Losartan and Chemo-Immunotherapy for Triple Negative Breast Cancer DOI Creative Commons
Qing Zhao, Xuexin He,

Xiyi Qin

et al.

Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13

Published: June 23, 2022

Triple-negative breast cancer (TNBC) is a particularly aggressive subtype of cancer, which relatively resistant to anti-programmed cell death-1 (α-PD1) therapy, characterized as non-immunogenic, dense stroma and accumulation M2 tumor-associated macrophages (TAMs). Despite progress in strategies deplete extracellular matrix (ECM) enhance tumor-cell immunogenicity, the combinatorial anti-cancer effects with α-PD1 need be explored. Here, we applied doxorubicin hydrochloride liposome (Dox-L) immunogenic death (ICD)-inducing nano-chemotherapy used losartan stroma-depleting agent improve efficacy (Losartan + Dox-L α-PD1). The results showed that could cause ECM reduction, facilitating enhanced delivery further dendritic (DC) maturation. Additionally, also alleviate hypoxia for TNBC, thus reprogramming pro-cancer TAMs M1 TAMs, successfully overcoming immune-suppressive microenvironment. These modifications led significant increase T cells’ infiltration augmented anti-tumor immunity exemplified by notable reduction tumor size lung metastases. In summary, our findings support combined treatment normalizes immunological-cold microenvironment, improves immuno-stimulation optimizes TNBC immunotherapy. A novel combinational strategy FDA-approved compounds proposed study may potentially useful clinical treatment.

Language: Английский

Citations

29
Exosomes and ultrasound: The future of theranostic applications DOI Creative Commons
Badrinathan Sridharan, Hae Gyun Lim

Materials Today Bio, Journal Year: 2023, Volume and Issue: 19, P. 100556 - 100556

Published: Jan. 20, 2023

Biomaterials and pertaining formulations have been very successful in various diagnostic therapeutic applications because of its ability to overcome pharmacological limitations. Some them gained significant focus the recent decade for their theranostic properties. Exosomes can be grouped as biomaterials, since they consist biological micro/macromolecules possess all properties a stable biomaterial with size nano range. Significant research has gone into isolation exploitation exosomes potential agent. However, limitations terms yield, efficacy, target specificity are continuously being addressed. On other hand, several nano/microformulations responsive physical or chemical alterations were successfully stimulated by tweaking characteristics surrounding environment in. termed photodynamic, sonodynamic thermodynamic systems. In this regard, ultrasound acoustic systems extensively studied towards altering which applied on. review, we detailed about separately, consisting conventional applications, drawbacks, developments addressing challenges. The information categorized sections that provide complete overview strategies diseases. Then ultrasound-based disease diagnosis therapy elaborated, special interest use enhancing efficacy nanomedicines nanodrug delivery systems, Finally, discussed exosomes, could future theranostics.

Language: Английский

Citations

22